Chemotherapy of lung cancer in the elderly

• Published in: Critical reviews in oncology/hematology 2002-03, Vol.41 (3), p.349-361
• Main Author: Frasci, Giuseppe
• Format: Article
• Language: English
• Subjects: Age Factors; Aged; Aged, 80 and over; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Chemotherapy; Clinical Trials as Topic; Elderly; Humans; Lung cancer; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Medical sciences; Multidimensional assessment; Pharmacology. Drug treatments; Prognosis
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/S1040-8428(01)00145-7

In the last few years it has become evident that the elderly lung cancer patient represents a peculiar individual with regard to both the tolerance to the tumor and its treatment. Age per se cannot be considered an adverse prognostic factor, however, the physiologic impairment of the functions of important organs like liver, kidney, bone marrow etc., may render more unpredictable the treatment-related toxicity, and moreover, the higher incidence of concomitant diseases which occurs with aging certainly translates in a worse survival outcome. As a consequence, a careful multidimensional evaluation (functional, emotional, socioeconomic status, comorbidities, etc.) should be preliminarily performed in patients eligible for chemotherapy treatment. Several approaches have been tested in elderly lung cancer patients. Different therapeutic attitudes exist, which first take into account the kind of histology (small cell lung cancer, SCLC and non-small cell lung cancer, NSCLC). Of course a more aggressive approach can be sometimes justified in an elderly SCLC patient in view of the high responsiveness of this disease, while more concerns exist about the use of aggressive chemotherapy regimen in elderly patients with NSCLC histology. In view of these considerations, more clinical trials are being planned to specifically assess the role of chemotherapy in this subset of patients. A brief review of the most important phase II and III trials conducted in elderly patients with either SCLC or NSCLC is provided here. A description of the most important still unsolved issues will be made, and an outline of the ongoing clinical trials in these patients will be provided.